{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:03:47Z","timestamp":1788609827885,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-026-05413-4","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:27:51Z","timestamp":1771244871000},"page":"3944-3956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Baseline CT imaging features combined with clinical indicators predict prognosis in unresectable HCC treated with HAIC plus targeted therapy and immunotherapy"],"prefix":"10.1007","volume":"51","author":[{"given":"Haiqin","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"3","key":"5413_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229\u201363. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"5413_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","volume":"150","author":"J Bruix","year":"2016","unstructured":"Bruix J, Reig M, Sherman M (2016) Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology 150(4):835\u2013853. https:\/\/doi.org\/10.1053\/j.gastro.2015.12.041","journal-title":"Gastroenterology"},{"issue":"1","key":"5413_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000449343","volume":"6","author":"M Kudo","year":"2016","unstructured":"Kudo M, Trevisani F, Abou-Alfa G K, et al. Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. Liver Cancer, 2016, 6(1): 16\u201326. https:\/\/doi.org\/10.1159\/000449343","journal-title":"Liver Cancer"},{"issue":"2","key":"5413_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jjco\/hyx180","volume":"48","author":"M Ikeda","year":"2018","unstructured":"Ikeda M, Morizane C, Ueno M, et al. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol, 2018, 48(2): 103\u201314. https:\/\/doi.org\/10.1093\/jjco\/hyx180","journal-title":"Jpn J Clin Oncol"},{"key":"5413_CR5","doi-asserted-by":"publisher","first-page":"175883592110027","DOI":"10.1177\/17588359211002720","volume":"13","author":"MK He","year":"2021","unstructured":"He M K, Liang R B, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol, 2021, 13: 17588359211002720. https:\/\/doi.org\/10.1177\/17588359211002720","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"5413_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1148\/radiol.211545","volume":"303","author":"K Zheng","year":"2022","unstructured":"Zheng K, Zhu X, Fu S, et al. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial. Radiology, 2022, 303(2): 455\u201364. https:\/\/doi.org\/10.1148\/radiol.211545","journal-title":"Radiology"},{"issue":"5","key":"5413_CR7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/jco.21.01963","volume":"40","author":"N Lyu","year":"2022","unstructured":"Lyu N, Wang X, Li J B, et al. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J Clin Oncol, 2022, 40(5): 468\u201380. https:\/\/doi.org\/10.1200\/jco.21.01963","journal-title":"J Clin Oncol"},{"issue":"7","key":"5413_CR8","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1097\/js9.0000000000001378","volume":"110","author":"R Guan","year":"2024","unstructured":"Guan R, Zhang N, Deng M, et al. Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors. Int J Surg, 2024, 110(7): 4062\u201373. https:\/\/doi.org\/10.1097\/js9.0000000000001378","journal-title":"Int J Surg"},{"issue":"3","key":"5413_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1148\/radiol.11081489","volume":"259","author":"RJ Lewandowski","year":"2011","unstructured":"Lewandowski R J, Geschwind J F, Liapi E, et al. Transcatheter intraarterial therapies: rationale and overview. Radiology, 2011, 259(3): 641\u201357. https:\/\/doi.org\/10.1148\/radiol.11081489","journal-title":"Radiology"},{"issue":"6","key":"5413_CR10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.4274\/dir.2023.232311","volume":"29","author":"PN Hien","year":"2023","unstructured":"Hien P N, Chun H J, Oh J S, et al. Usefulness of tumor perfusion on cone-beam CT after hepatic arterial infusion port implantation for evaluating tumor response to hepatic arterial infusion chemotherapy in hepatocellular carcinoma treatment. Diagn Interv Radiol, 2023, 29(6): 832\u20137. https:\/\/doi.org\/10.4274\/dir.2023.232311","journal-title":"Diagn Interv Radiol"},{"issue":"1","key":"5413_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1148\/radiol.2021203614","volume":"300","author":"Z Feng","year":"2021","unstructured":"Feng Z, Li H, Zhao H, et al. Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma. Radiology, 2021, 300(1): 219\u201329. https:\/\/doi.org\/10.1148\/radiol.2021203614","journal-title":"Radiology"},{"issue":"1","key":"5413_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00535-004-1494-7","volume":"40","author":"T YAMASAKI","year":"2005","unstructured":"YAMASAKI T, KIMURA T, KUROKAWA F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol, 2005, 40(1): 70\u20138. https:\/\/doi.org\/10.1007\/s00535-004-1494-7","journal-title":"J Gastroenterol"},{"key":"5413_CR13","doi-asserted-by":"publisher","first-page":"109890","DOI":"10.1016\/j.ejrad.2021.109890","volume":"142","author":"J Mei","year":"2021","unstructured":"Mei J, Lin W P, Shi F, et al. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. Eur J Radiol, 2021, 142: 109890. https:\/\/doi.org\/10.1016\/j.ejrad.2021.109890","journal-title":"Eur J Radiol"},{"issue":"42","key":"5413_CR14","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.3748\/wjg.v22.i42.9279","volume":"22","author":"WM Cong","year":"2016","unstructured":"Cong W M, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol, 2016, 22(42): 9279\u201387. https:\/\/doi.org\/10.3748\/wjg.v22.i42.9279","journal-title":"World J Gastroenterol"},{"issue":"2","key":"5413_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00261-018-1758-y","volume":"44","author":"C An","year":"2019","unstructured":"An C, Kim M J. Imaging features related with prognosis of hepatocellular carcinoma. Abdom Radiol (NY), 2019, 44(2): 509\u201316. https:\/\/doi.org\/10.1007\/s00261-018-1758-y","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"5413_CR16","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1148\/rg.2021200205","volume":"41","author":"GM Cunha","year":"2021","unstructured":"Cunha GM, Fowler K J, Roudenko A, et al. How to Use LI-RADS to Report Liver CT and MRI Observations. Radiographics, 2021, 41(5): 1352\u201367. https:\/\/doi.org\/10.1148\/rg.2021200205","journal-title":"Radiographics"},{"issue":"1","key":"5413_CR17","doi-asserted-by":"publisher","first-page":"e222801","DOI":"10.1148\/radiol.222801","volume":"307","author":"V Chernyak","year":"2023","unstructured":"Chernyak V, Fowler K J, Do R K G, et al. LI-RADS: Looking Back, Looking Forward. Radiology, 2023, 307(1): e222801. https:\/\/doi.org\/10.1148\/radiol.222801","journal-title":"Radiology"},{"issue":"2","key":"5413_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00595-013-0585-6","volume":"44","author":"S Katagiri","year":"2014","unstructured":"Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today, 2014, 44(2): 219\u201326. https:\/\/doi.org\/10.1007\/s00595-013-0585-6","journal-title":"Surg Today"},{"issue":"2","key":"5413_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet J M, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol, 2020, 72(2): 288\u2013306. https:\/\/doi.org\/10.1016\/j.jhep.2019.09.026","journal-title":"J Hepatol"},{"issue":"2","key":"5413_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/jco.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Li Q J, He M K, Chen H W, et al. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol, 2022, 40(2): 150\u201360. https:\/\/doi.org\/10.1200\/jco.21.00608","journal-title":"J Clin Oncol"},{"key":"5413_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193195","author":"K Yoshimitsu","year":"2025","unstructured":"Yoshimitsu K, Nishie A, Takayama Y, et al. The Washout of Hepatocellular Carcinoma at Portal Venous Phase vs. Equilibrium Phase: Radiological and Clinicopathological Implication. Cancers (Basel), 2025. https:\/\/doi.org\/10.3390\/cancers17193195","journal-title":"Cancers (Basel)"},{"issue":"6","key":"5413_CR22","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1148\/rg.2021210019","volume":"41","author":"N Consul","year":"2021","unstructured":"Consul N, Sirlin C B, Chernyak V, et al. Imaging Features at the Periphery: Hemodynamics, Pathophysiology, and Effect on LI-RADS Categorization. Radiographics, 2021, 41(6): 1657\u201375. https:\/\/doi.org\/10.1148\/rg.2021210019","journal-title":"Radiographics"},{"issue":"1017","key":"5413_CR23","doi-asserted-by":"publisher","first-page":"e573-83","DOI":"10.1259\/bjr\/86767895","volume":"85","author":"JH Lee","year":"2012","unstructured":"Lee J H, Lee J M, Kim S J, et al. Enhancement patterns of hepatocellular carcinomas on multiphasicmultidetector row CT: comparison with pathological differentiation. Br J Radiol, 2012, 85(1017): e573-83. https:\/\/doi.org\/10.1259\/bjr\/86767895","journal-title":"Br J Radiol"},{"key":"5413_CR24","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2147\/jhc.S328198","volume":"8","author":"A Murtha-Lemekhova","year":"2021","unstructured":"Murtha-Lemekhova A, Fuchs J, Schulz E, et al. Scirrhous Hepatocellular Carcinoma: Systematic Review and Pooled Data Analysis of Clinical, Radiological, and Histopathological Features. J Hepatocell Carcinoma, 2021, 8: 1269\u201379. https:\/\/doi.org\/10.2147\/jhc.S328198","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"5413_CR25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.jhep.2022.03.036","volume":"77","author":"C Li","year":"2022","unstructured":"Li C, Ouyang W, Yang T. The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma. J Hepatol, 2022, 77(3): 890\u20131. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.036","journal-title":"J Hepatol"},{"key":"5413_CR26","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2147\/jhc.S544589","volume":"12","author":"QB Wang","year":"2025","unstructured":"Wang Q B, Luo W L, Li Y K, et al. Tumor Compression of the Hepatic or Portal Vein Predicts the Presence of Microvascular Invasion and Satellite Nodules in Hepatocellular Carcinoma: A Retrospective Study. J Hepatocell Carcinoma, 2025, 12: 2055\u201367. https:\/\/doi.org\/10.2147\/jhc.S544589","journal-title":"J Hepatocell Carcinoma"},{"key":"5413_CR27","doi-asserted-by":"publisher","first-page":"1274474","DOI":"10.3389\/fimmu.2024.1274474","volume":"15","author":"F Riaz","year":"2024","unstructured":"Riaz F, Zhang J, Pan F. Forces at play: exploring factors affecting the cancer metastasis. Front Immunol, 2024, 15: 1274474. https:\/\/doi.org\/10.3389\/fimmu.2024.1274474","journal-title":"Front Immunol"},{"key":"5413_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz0868","author":"HT Nia","year":"2020","unstructured":"Nia H T, Munn L L, Jain R K. Physical traits of cancer. Science, 2020. https:\/\/doi.org\/10.1126\/science.aaz0868","journal-title":"Science"},{"key":"5413_CR29","doi-asserted-by":"publisher","first-page":"1467602","DOI":"10.3389\/fimmu.2024.1467602","volume":"15","author":"X Feng","year":"2024","unstructured":"Feng X, Cao F, Wu X, et al. Targeting extracellular matrix stiffness for cancer therapy. Front Immunol, 2024, 15: 1467602. https:\/\/doi.org\/10.3389\/fimmu.2024.1467602","journal-title":"Front Immunol"},{"issue":"6","key":"5413_CR30","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.jhep.2015.01.022","volume":"62","author":"BK Kim","year":"2015","unstructured":"Kim B K, Kim S U, Kim K A, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol, 2015, 62(6): 1304\u201310. https:\/\/doi.org\/10.1016\/j.jhep.2015.01.022","journal-title":"J Hepatol"},{"issue":"7","key":"5413_CR31","doi-asserted-by":"publisher","first-page":"e0133488","DOI":"10.1371\/journal.pone.0133488","volume":"10","author":"B Vincenzi","year":"2015","unstructured":"Vincenzi B, DI Maio M, Silletta M, et al. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One, 2015, 10(7): e0133488. https:\/\/doi.org\/10.1371\/journal.pone.0133488","journal-title":"PLoS One"},{"issue":"1","key":"5413_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018, 69(1): 182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"issue":"8","key":"5413_CR33","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1007\/s00432-022-04467-3","volume":"149","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Huang F, Liu S, et al. Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score. J Cancer Res Clin Oncol, 2023, 149(8): 5181\u201392. https:\/\/doi.org\/10.1007\/s00432-022-04467-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"5413_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092550","author":"PH Huang","year":"2022","unstructured":"Huang P H, Yu J, Chu Y Y, et al. Child-Pugh Score and ABCG2-rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib. J Clin Med, 2022. https:\/\/doi.org\/10.3390\/jcm11092550","journal-title":"J Clin Med"},{"issue":"3","key":"5413_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/jso.25184","volume":"118","author":"YY Wang","year":"2018","unstructured":"Wang Y Y, Zhao X H, Ma L, et al. Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma. J Surg Oncol, 2018, 118(3): 440\u20135. https:\/\/doi.org\/10.1002\/jso.25184","journal-title":"J Surg Oncol"},{"issue":"1063","key":"5413_CR36","doi-asserted-by":"publisher","first-page":"20150945","DOI":"10.1259\/bjr.20150945","volume":"89","author":"E Okazaki","year":"2016","unstructured":"Okazaki E, Yamamoto A, Nishida N, et al. Three-dimensional conformal radiotherapy for locally advanced hepatocellular carcinoma with portal vein tumour thrombosis: evaluating effectiveness of the model for end-stage liver disease (MELD) score compared with the Child-Pugh classification. Br J Radiol, 2016, 89(1063): 20150945. https:\/\/doi.org\/10.1259\/bjr.20150945","journal-title":"Br J Radiol"},{"issue":"3","key":"5413_CR37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000472262","volume":"6","author":"T Terashima","year":"2017","unstructured":"Terashima T, Yamashita T, Arai K, et al. Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. Liver Cancer, 2017, 6(3): 236\u201349. https:\/\/doi.org\/10.1159\/000472262","journal-title":"Liver Cancer"},{"issue":"11","key":"5413_CR38","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.7150\/jca.19181","volume":"8","author":"XP Wang","year":"2017","unstructured":"Wang X P, Mao M J, He Z L, et al. A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. Journal of Cancer, 2017, 8(11): 2079\u201387. https:\/\/doi.org\/10.7150\/jca.19181","journal-title":"Journal of Cancer"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05413-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05413-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05413-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:45:16Z","timestamp":1784609116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05413-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["5413"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05413-4","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}